At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Post-Mkt 01-15 17:37:10 EST
4.24
+0.06
+1.44%
盘后4.27
+0.03+0.70%
17:19 EST
High4.40Low4.05Vol4.54M
Open4.15D1 Closing4.18Amplitude8.37%
Mkt Cap442.41MTradable Cap440.96MTotal Shares104.34M
T/O19.22MT/O Rate4.37%Tradable Shares104.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Altimmune Director Wayne Pisano Acquires Common Shares
Reuters  ·  01-10
Altimmune Director Wayne Pisano Acquires Common Shares
Owens & Minor Issues Amended Report on P&HS Business Sale
Reuters  ·  01-06
Owens & Minor Issues Amended Report on P&HS Business Sale
Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares
Reuters  ·  01-06
Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares
BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
Reuters  ·  01-06
BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
Benzinga_recent_news  ·  01-05
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug
THOMSON REUTERS  ·  01-05
Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
Reuters  ·  01-05
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug
Reuters  ·  01-05
BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug
Altimmune Earns FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Reuters  ·  01-05
Altimmune Earns FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in Mash
THOMSON REUTERS  ·  01-05
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in Mash
Altimmune Director Diane Jorkasky Acquires Common Shares
Reuters  ·  2025-12-30
Altimmune Director Diane Jorkasky Acquires Common Shares
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares
Simply Wall St.  ·  2025-12-28
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares
Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares
Reuters  ·  2025-12-23
Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Reuters  ·  2025-12-19
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
Reuters  ·  2025-12-19
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
Altimmune Shares Climb 6.9% Premarket After Positive Trial Data
THOMSON REUTERS  ·  2025-12-19
Altimmune Shares Climb 6.9% Premarket After Positive Trial Data
Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial
Reuters  ·  2025-12-19
Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial
Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss
THOMSON REUTERS  ·  2025-12-19
Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss
Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial
THOMSON REUTERS  ·  2025-12-19
Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters  ·  2025-12-12
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--